Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3
出版年份 2018 全文链接
标题
Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3
作者
关键词
-
出版物
ONCOGENE
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-04-30
DOI
10.1038/s41388-018-0276-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures
- (2017) Dae Ho Lee PHARMACOLOGY & THERAPEUTICS
- EMT: 2016
- (2016) M. Angela Nieto et al. CELL
- Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation
- (2016) Silvia La Monica et al. Journal of Thoracic Oncology
- miRNA Deregulation in Cancer Cells and the Tumor Microenvironment
- (2016) R. Rupaimoole et al. Cancer Discovery
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Combinatorial Action of MicroRNAslet-7and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation
- (2015) Carlos Stahlhut et al. CELL CYCLE
- Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
- (2015) Laetitia Seguin et al. TRENDS IN CELL BIOLOGY
- Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma
- (2015) Cuiping Wang et al. TUMOR BIOLOGY
- MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET
- (2014) Jian-Ya Zhou et al. CANCER LETTERS
- Aberrant Regulation and Function of MicroRNAs in Cancer
- (2014) Brian D. Adams et al. CURRENT BIOLOGY
- Targeting FAK in human cancer: from finding to first clinical trials
- (2014) Vita Golubovskaya Frontiers in Bioscience-Landmark
- An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition
- (2014) Laetitia Seguin et al. NATURE CELL BIOLOGY
- Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells
- (2013) K. Shien et al. CANCER RESEARCH
- Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin 1/Src/Akt-Driven Bypass Signaling
- (2013) R. Kanda et al. CANCER RESEARCH
- Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model
- (2013) Hiromi Hayakawa et al. CANCER SCIENCE
- Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties
- (2013) Thomas BERTERO et al. CELL CYCLE
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
- (2013) Bing Li et al. LUNG CANCER
- MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma
- (2012) Wen Wang et al. CARCINOGENESIS
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- MiR-663, a microRNA targeting p21 WAF1/CIP1 , promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma
- (2012) C Yi et al. ONCOGENE
- Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma
- (2012) Wen Wang WORLD JOURNAL OF GASTROENTEROLOGY
- The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma
- (2011) Deniz M Özata et al. ENDOCRINE-RELATED CANCER
- Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
- (2011) Kenichi Suda et al. Journal of Thoracic Oncology
- Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells
- (2011) D Kong et al. ONCOGENE
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- The role of the miR-200 family in epithelial-mesenchymal transition
- (2010) Perry S. Mongroo et al. CANCER BIOLOGY & THERAPY
- Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor-Activating Mutations
- (2010) C. Yamamoto et al. CANCER RESEARCH
- Oncogenic Role of miR-483-3p at the IGF2/483 Locus
- (2010) A. Veronese et al. CANCER RESEARCH
- Regulation of Insulin-like Growth Factor–Mammalian Target of Rapamycin Signaling by MicroRNA in Childhood Adrenocortical Tumors
- (2010) Mabrouka Doghman et al. CANCER RESEARCH
- MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer
- (2010) Jun Hao et al. FEBS LETTERS
- Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer
- (2010) Lixia Ju et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors
- (2010) Xi Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs
- (2010) Jin-Haeng Chung et al. LUNG CANCER
- Resistance May Not Be Futile: microRNA Biomarkers for Chemoresistance and Potential Therapeutics
- (2010) K. E. Allen et al. MOLECULAR CANCER THERAPEUTICS
- RETRACTED: A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis
- (2009) Scott Valastyan et al. CELL
- CDKN2A,NF2, andJUNare dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis
- (2009) Mohamed Guled et al. GENES CHROMOSOMES & CANCER
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started